Peptide nanoparticles as novel immunogens: Design and analysis of a prototypic severe acute respiratory syndrome vaccine

Chemical Biology and Drug Design

Volumn 73, Issue 1, 2009, Pages 53-61

  Pimentel, Tais A P F ^a   Yan, Zhe ^b   Jeffers, Scott A ^b   Holmes, Kathryn V ^b   Hodges, Robert S ^b   Burkhard, Peter ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Coiled coils; Peptide nanoparticles; Protein design; Repetitive antigen display; SARS coronavirus; SARS spike glycoprotein; Subunit vaccines

Indexed keywords

ANTIBODY; ANTIGEN; CARBOXY TERMINAL TELOPEPTIDE; NANOPARTICLE; P6HRC 1 PEPTIDE NANOPARTICLE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG DESIGN; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; PROTEIN CONFORMATION; PROTEIN SUBUNITS; RECOMBINANT FUSION PROTEINS; SARS VIRUS; SEQUENCE HOMOLOGY, AMINO ACID; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES;

ANIMALIA; CORONAVIRUS; MUS; SARS CORONAVIRUS;

EID: 58149095758     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00746.x     Document Type: Article

References (37)

1. Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S.N., Khattra J. et al. (2003) The genome sequence of the SARS-associated coronavirus. Science 300 : 1399 1404.
2. Nicholls J., Dong X., Jiang G., Peiris M. (2003) SARS: clinical virology and pathogenesis. Respirology 8 : S6 S8.
3. Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W. et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science 302 : 276 278.
4. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Wang H. et al. (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science 310 : 676 679.
5. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., Manon C. et al. (2006) A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24 : 3624 3631.
6. Tripet B., Howard M.W., Jobling M., Holmes R.K., Holmes K.V., Hodges R.S. (2004) Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem 279 : 20836 20849.
7. McReynolds S., Jiang S., Guo Y., Celigoy J., Schar C., Rong L., Caffrey M. et al. (2008) Characterization of the prefusion and transition states of severe acute respiratory syndrome coronavirus S2-HR2. Biochemistry 47 : 6802 6808.
8. Xu Y., Lou Z., Liu Y., Pang H., Tien P., Gao G.F., Rao Z. et al. (2004) Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 279 : 49414 49419.
9. Saif L.J. (1993) Coronavirus immunogens. Vet Microbiol 37 : 285 297.
10. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., Subbarao K. et al. (2004) Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101 : 6641 6646.
11. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., Claire M.S., Murphy B.R. et al. (2004) Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 : 2122 2127.
12. Huang J., Cao Y., Du J., Bu X., Ma R., Wu C. (2007) Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 25 : 6981 6991.
13. Kitabatake M., Inoue S., Yasui F., Yokochi S., Arai M., Morita K., Shida H. et al. (2007) SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. Vaccine 25 : 630 637.
14. Lokugamage K.G., Yoshikawa-Iwata N., Ito N., Watts D.M., Wyde P.R., Wang N., Newman P. et al. (2008) Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 26 : 797 808.
15. Liniger M., Zuniga A., Tamin A., Azzouz-Morin T.N., Knuchel M., Marty R.R., Wiegand M. et al. (2008) Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 26 : 2164 2174.
16. Kam Y.W., Kien F., Roberts A., Cheung Y.C., Lamirande E.W., Vogel L., Chu S.L. et al. (2007) Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine 25 : 729 740.
17. Czub M., Weingartl H., Czub S., He R., Cao J. (2005) Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23 : 2273 2279.
18. Corapi W.V., Olsen C.W., Scott F.W. (1992) Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol 66 : 6695 6705.
19. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., Jiang S. et al. (2004) Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324 : 773 781.
20. Du L., Zhao G., He Y., Guo Y., Zheng B., Jiang S., Zhou Y. et al. (2007) Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25 : 2832 2838.
21. Tripet B., Kao D.J., Jeffers S.A., Holmes K.V., Hodges R.S. (2006) Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus. J Struct Biol 155 : 176 194.
22. Raman S., Machaidze G., Lustig A., Aebi U., Burkhard P. (2006) Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomed Nanotechnol Biol Med 2 : 95 102.
23. Burkhard P., Meier M., Lustig A. (2000) Design of a minimal protein oligomerization domain by a structural approach. Protein Sci 9 : 2294 2301.
24. Harrison S.C. (2008) Viral membrane fusion. Nat Struct Mol Biol 15 : 690 698.
25. Laue T.M., Shah B.D., Ridgeway T.M., Pelletier S.L. (1992) Analytical Ultracentrifugation in Biochemistry and Polymer Science. London : Royal Society of Chemistry p. 90 125.
26. Schuck P. (2000) Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling. Biophys J 78 : 1606 1619.
27. Stafford W.F. (1992) Boundary analysis in sedimentation transport experiments: a procedure for obtaining sedimentation coefficient distributions using the time derivative of the concentration profile. Anal Biochem 203 : 295 301.
28. Philo J.S. (2000) A method for directly fitting the time derivative of sedimentation velocity data and an alternative algorithm for calculating sedimentation coefficient distribution functions. Anal Biochem 279 : 151 163.
29. Philo J.S. (2006) Improved methods for fitting sedimentation coefficient distributions derived by time-derivative techniques. Anal Biochem 354 : 238 246.
30. Branden C., Tooze J. (1999) Introduction to Protein Structure, 2nd edn. New York, NY : Garland Publishing.
31. Zhou N.E., Monera O.D., Kay C.M., Hodges R.S. (1994) α-Helical propensities of amino acids in the hydrophobic face of an amphipathic α-helix. Protein Pept Lett 1 : 114 119.
32. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., Plebanski M. et al. (2006) Pathogen recognition and development of particulate vaccines: does size matter? Methods 40 : 1 9.
33. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F.C. et al. (2004) Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173 : 3148 3154.
34. Padilla J.E., Colovos C., Yeates T.O. (2001) Nanohedra: using symmetry to design self assembling protein cages, layers, crystals, and filaments. Proc Natl Acad Sci USA 98 : 2217 2221.
35. Harbury P.B., Kim P.S., Alber T. (1994) Crystal structure of an isoleucine-zipper trimer. Nature 371 : 80 83.
36. Harbury P., Zhang T., Kim P., Alber T. (1993) A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262 : 1401 1407.
37. Hodges R., Heaton R., Parker J., Molday L., Molday R. (1988) Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin. J Biol Chem 263 : 11768 11775.